SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
erippetoe
jhcimmu
From: ghettogoulash7/30/2025 9:46:10 AM
2 Recommendations   of 63320
 
SRPT plunged from $63 to $36 when Prasad was named director of CBER, based upon his previous criticism of Elevidys. (Impressive forecast) Non-ambulatory and LGMD should get a fair evaluation now, although the three deaths remain disconcerting. European regulators, who just rejected Elevidys in ambulatory based upon recent events at FDA, might now take second look.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News